HDAC inhibitors target crucial oncogene and tumor immune microenvironment in TNBC
Dr. Rumela Chakrabarti's team found that the protein ΔNp63 helps triple-negative breast cancer suppress immunity in mice, and the HDAC inhibitor Quisinostat lowered it, slowing tumour growth and spread.
Read the original paper
Triple-negative breast cancer (TNBC) is a particularly aggressive form of breast cancer that lacks hormonal receptors.. Current traditional treatments include chemo and radio therapy, which have limited efficacy in several advanced TNBC patients, suggesting need to find better drug targets. Recently, scientists have discovered a new potential target for treatment: a protein called ΔNp63. This protein appears to play a significant role in helping the cancer grow and spread, as well as in the cancer cells’ ability to evade the body’s immune system. Understanding how ΔNp63 works could lead to more effective treatments for those battling this tough cancer.
A team of researchers led by Dr. Rumela Chakrabarti along with Dr. Ukjin Kim and Javier Maiz from the University of Miami, and Dr. Rahul Debnath, Joshua Rico, and Dr. Mario Blanco from the University of Pennsylvania, along with Professor Satrajit Sinha from The State University of New York, has shed light on the critical role of ΔNp63 in the progression and treatment of TNBC. The study focuses on how ΔNp63 influences myeloid-derived suppressor cell (MDSC) survival and metabolism, providing a potential target for improving TNBC therapies. Their findings are published in the peer-reviewed journal iScience.
The study demonstrates that ΔNp63 is highly expressed in TNBC tumors and plays a pivotal role in tumor progression and metastasis. Targeting ΔNp63 using both inducible CRISPR knockout techniques and the histone deacetylase (HDAC) inhibitor Quisinostat resulted in reduced tumor growth and metastasis. The researchers found that ΔNp63 promotes MDSC survival through tumor necrosis factor alpha (TNF-α), reshaping the tumor microenvironment by altering immune cell populations. Decreasing ΔNp63 levels led to a reduction in CD4+ and FOXP3+ T-cells while increasing CD8+ T-cells, suggesting a shift from immune evasion to immune surveillance.
Dr. Chakrabarti explained, “Our research shows that ΔNp63 reprograms the immunosuppressive functions of MDSCs in TNBC. This highlights the potential benefits of targeting ΔNp63 in chemotherapy-resistant TNBC.”
The researchers employed various models, including genetically engineered mouse models (GEMM) and syngeneic TNBC allografts, to study the effects of ΔNp63 inhibition on established tumors. They observed that conditional loss of ΔNp63 in spontaneous TNBC tumors resulted in decreased tumor growth and metastasis. Immunostaining revealed reduced MDSC infiltration and fewer metastatic tumor cells in lymph nodes. Moreover, RNA sequencing analysis indicated that loss of ΔNp63 affects multiple MDSC properties, such as lipid metabolism, chemotaxis, and migration.
In addition to genetic approaches, the team explored pharmacological inhibition of ΔNp63 using Quisinostat. This HDAC inhibitor not only reduced ΔNp63 protein levels but also significantly inhibited TNBC tumor progression and metastasis. The treatment altered the tumor immune landscape, decreasing MDSC and regulatory T-cell populations while increasing cytotoxic T-cells. These changes suggest that Quisinostat can enhance the anti-tumor immune response in TNBC.
Dr. Chakrabarti stated, “Targeting ΔNp63 with Quisinostat not only suppresses tumor growth but also modifies the immune environment to favor anti-tumor immunity. This dual action makes it a promising candidate for combination therapies.”
The study’s findings underscore the potential of targeting ΔNp63 in TNBC to improve chemotherapy outcomes. The researchers demonstrated that combining ΔNp63 inhibition with conventional chemotherapy sensitizes TNBC tumors to treatment, leading to greater tumor suppression and reduced metastasis. This combination also decreased MDSC numbers and increased their apoptosis, indicating a compromised immunosuppressive environment.
In summary, the research by Dr. Chakrabarti and her team provides compelling evidence that ΔNp63 is a crucial regulator of TNBC progression and a viable target for enhancing chemotherapy efficacy. By disrupting the survival and function of MDSCs, ΔNp63 inhibition not only hampers tumor growth but also promotes a more robust anti-tumor immune response. These insights pave the way for developing new therapeutic strategies to combat the aggressive nature of TNBC.
About the researchers
Journal reference
Kim, U., Debnath, R., Maiz, J. E., Rico, J., Sinha, S., Blanco, M. A., & Chakrabarti, R. (2024). “ΔNp63 regulates MDSC survival and metabolism in triple-negative breast cancer.” iScience, 27, 109366. DOI: https://doi.org/10.1016/j.isci.2024.109366




